Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Characteristics	All (n=16)	IFN neg. (n=8)	IFN pos. (n=8)
Female sex, no. (%)	12 (75%)	6 (75%)	6 (75%)
Age, year	55.8±10.1	59.3±7.5	52.4±11.7
Swollen joints, no.	5.4±2.0	4.9±1.5	6.0±2.3
Tender joints, no.	12.0±10.0	6.4±3.6	17.6±11.4
CDAI	26.7±13.7	18.0±5.9	34.3±14.2
SDAI	28.0±14.2	19.0±6.5	35.9±14.7
CRP (mg/dl)	1.3±1.0	1.1±1.2	1.6±0.8
ESR (mm/hour)	21.6±24.1	16.4±21.0	27.6±27.6
CRP/ESR ratio	0.07±0.06	0.05±0.06	0.09±0.05
RF positive, no. (%)	12 (75%)	6 (75%)	6 (75%)
RF (IU/ml)	150.6±246.5	109.4±235.7	191.0±266.0
Anti-CCP positive, no. (%)	10 (63%)	4 (50%)	6 (75%)
Anti-CCP (U/ml)	206.7±164.1	167.4±176.3	246.0±151.9

Supplementary Table 1
Demographic and clinical characteristics of patients at screening. Only data of first screening visit are shown. Unless other stated, data show mean±SD.
Abbreviations: anti-CCP, Anti-cyclic citrullinated peptide antibody; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sedimentation rate; no., number; SDAI, simplified disease activity index; RF, rheumatoid factor;

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

RMD Open